Login to Your Account

Gilead's Much-Awaited Quad Gets Timely FDA Nod in HIV

By Jennifer Boggs
Managing Editor

Tuesday, August 28, 2012

Gilead Sciences Inc.'s four-drug, single-tablet HIV drug Quad got its much-anticipated approval Monday, and the drug is expected to shore up the firm's top-selling HIV franchise, which brought in $7.05 billion in revenue in 2011 but faces patent expiries starting in 2018.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription